The Coronavirus Disease presents a significant threat to global schooling & also avoided education the pandemics impact on education will be much more significant for healthcare, students, who would require rotational preparation, laboratory experience, internships and seminars, meetings and clerkships, and technical and organisational evaluation and assistance and some other issues like lack of broadband coverage, relatively large out-of-pocket costs associated with Internet data packs, and an epileptic power supply.

The first week of April of this year is again forcing to recall the last year’s pandemic. It was January, 2020, when some patients were identified as COVID-19 positive, at February of last year it was confirmed for the human to human transmission in Wuhan. Lastly, in the march of March, 2020, WHO announced this spread of corona virus as pandemic (1). We have learnt a lot to protect ourselves from the pandemic like- wearing of mask, social distancing and use of sanitizer. Several articles have been published regarding the structure and mode of transmission of the virus. The pharmacology of different available drugs, WHO guidelines, home remedies and many more was the review topics of that current time. The effect of the corona virus on human organs was the prime interest. Psychological and behavioral signs of people of all classes at post corona era was the research topics (2-9). We were successful to control the spread of pandemic in 2020 (Table 1 and Graph 1)(10) and maybe we have neglected the practice of maintenance of hygienic condition in our daytoday life. The result was clearly in front of us.

BCS and Biopharmaceutics Drug disposition Classification System are free, not contending, grouping frame works that intend to increase, rearrange, and grow drug advancement. Albeit the two frameworks depend on characterizing drugs and new sub-atomic elements into four classes utilizing a similar solubility rules, they contrast in the basis for penetrability and have various purposes. Here, the subtleties and utilizations of the two frameworks are checked on with specific accentuation of their job in drug improvement.

Bedaquiline use as first novel drug which has been approved by the US Food and Drug Administration (FDA) in December 2012 for the treastment of MDR-TB. Bedaquiline is a type of novel reserved antitubercular drug belongs to diarylquinoline class. Bedaquiline acts on Mycobacterium tuberculosis, which is efficacious in rifampin,Isoniazidas well as other antituberculardrugsresistant by directly inhibiting ATP synthase enzyme. The aim of the study is to review the efficacy of bedaquilinein multidrug-resistant tuberculosis. A website based latest research which has been done by screening of different reputed research article journals, conference and review articles related to the use of bedaquiline in multidrug-resistant tuberculosis. In multidrug-resistant tuberculosis, bedaquiline is the most effectiveantituberculardrug as compare to other second line anti-mycobacterial agents. After reviewing the different article based on efficacy of bedaquiline, this drug is more efficacious in the patients with MDR-TB and it could improve the quality of life in MDR-TB patients.

A simple isocratic and rapid reverse phase high performance liquid chromatographic (RP-HPLC) method was developed and successively validated stability for the estimation of Sitagliptin and Metformin HCL. Sitagliptin and Metformin HCL were resolved on an isocratic method, C8 Column, mobile phase utilizing a composition of 2.34g of Sodium 1-Octane Sulfonate Monohydrate : Acetonitrile(67:33 v/v pH 3.0) at a flow rate of 1.0 mL/min with UV detection at 210 nm. Retention Time of Sitagliptin and Metformin HCL were 13 min and 3.5 min respectively. RP-HPLC method for determination as well as force degradation study of Sitagliptin and Metformin HCl was Validated.The results of specific ,precise, accurate, linear, robust, rugged were proved within the limits as per ICH guidelines. The method could be used to select the storage condition improving the manufacturing process and for routine analysis of Sitagliptin and Metformin HCL in their combined dosage forms.